MGX earnings analysis
What we found in MGX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Metagenomi remains an early-stage, loss-making biotechnology company, reporting negative collaboration revenue of $0.257 million and diluted EPS of negative $0.73. Six-month net loss increased to $50.5 million from $44.9 million year over year, while liquidity of $120.7 million provides at least 12 months of funding under the current plan. The filing highlights substantial financing needs, heightened MGX-001 development uncertainty due to high FVIII variability, and unresolved securities litigation, with no numeric revenue or EPS guidance provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $120.7M liquidity supports near-term operations
- Cash, cash equivalents and available-for-sale marketable securities totaled $120.7 million as of June 30, 2026, which management expects will fund operations and capital expenditures for at least the next 12 months.
- Development spending remains funded
- The company reported six-month net losses of $50.5 million for the period ended June 30, 2026, compared with $44.9 million for the same period in 2025, a $5.6 million increase.
- In-house clinical manufacturing capability
- Management stated that it operates a cGMP manufacturing facility capable of manufacturing clinical-grade nucleases and mRNA, supporting wholly owned and collaboration programs.
- R&D remains the workforce priority
- The company had 113 full-time employees as of June 30, 2026, including 92 employees in research, development and technical operations.
- No material control deficiencies reported
- The company reported effective disclosure controls and procedures as of June 30, 2026, and disclosed no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Minimal and volatile collaboration revenue
- Collaboration revenue was negative $0.257 million and diluted EPS was negative $0.73, underscoring the lack of a recurring product-revenue base.
- Operating losses continue to widen
- The company reported net losses of $50.5 million for the six months ended June 30, 2026, versus $44.9 million in the prior-year period, and an accumulated deficit of $361.4 million as of June 30, 2026.
- Future financing and dilution risk
- Although liquidity was $120.7 million as of June 30, 2026, the company states that substantial additional funding will be required and is subject to the Form S-3 Baby Shelf Rule limiting primary offerings to one-third of non-affiliate market value.
- MGX-001 data may delay development
- The filing identifies new or heightened uncertainty around MGX-001: nonhuman-primate studies demonstrated high activity and high variability related to FVIII, and the company has commenced additional studies and may consider alternatives to its bioengineered FVIII construct.
- Securities litigation remains unresolved
- The company disclosed that the Securities Action filed on September 26, 2024 is currently in discovery after the court granted-in-part and denied-in-part the motion to dismiss on March 24, 2026; no loss estimate can currently be made.
- AI and data-privacy compliance exposure
- The filing adds material AI-related regulatory and compliance exposure: most provisions of the EU AI Act are scheduled to become effective on August 2, 2026, while the company states its data-privacy program is in its early stages and has not yet assessed compliance with all applicable requirements.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.73
- Segment
- Collaboration revenue: -$0.257 million; no additional segment revenue breakdown was disclosed
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that existing cash, cash equivalents and available-for-sale marketable securities of $120.7 million should fund operating expenses and capital expenditures for at least the next 12 months from the filing date.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 11, 2026
- Metagenomi Therapeutics reported its financial results for Q1 2026, showing a significant drop in collaboration revenue to $1.25 million from $4.13 million a year earlier, which highlights the challenges in sustaining…
- 10-K · March 5, 2026
- Metagenomi Therapeutics reported a net loss of $87.9 million for the fiscal year ended December 31, 2025, compared to a loss of $78.1 million in 2024. Revenue from collaboration agreements dropped significantly to $25.2…
- 10-Q · November 12, 2025
- Metagenomi reported Q3 2025 results, showing a revenue of $8.659 million, a slight increase from $8.534 million in Q3 2024, but a decline in net loss to $20.393 million from $18.773 million in the prior year. The…
- 10-Q · August 12, 2025
- Metagenomi, Inc. reported a decline in revenue and wider losses for Q2 2025 compared to previous periods. The company generated $8.5 million in collaboration revenue, down from $20 million a year earlier, with a notable…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MGX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever